Drug Profile
Libvatrep - Novartis
Alternative Names: SAF-312Latest Information Update: 05 Oct 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Benzonitrile; Non-opioid analgesics; Quinazolines; Small molecules; Urologics
- Mechanism of Action TRPV cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurogenic bladder; Postoperative pain
Most Recent Events
- 29 Sep 2023 Bausch and Lomb acquires libvatrep from Novartis
- 30 Jun 2023 Bausch & Lomb enters into a definitive agreement with Novartis for Lifitegrast and Libvatrep
- 07 Jun 2023 Novartis completes the phase II SAHARA trial in Postoperative pain in USA, UK and Japan (Topical, Suspension) (NCT04630158)